logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
MNPR
Monopar Therapeutics Inc.
96.03
3 x 96.60
1 x 98.40
bid
ask
+
1.00
1.05%
11:20 AM
timesize
Ytd47.06%
1y173.12%
93.59
day range
100.00
29.18
52 week range
105.00
Open95.44Prev Close95.03Low93.59High100.00Mkt Cap643.31M
Vol23.92KAvg Vol172.05KEPS-1.93P/EN/AForward P/E-10.17
Beta1.10Short Ratio0.15Inst. Own24.47%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg64.05200-d Avg68.351yr Est27.33

MNPR News

benzinga.com
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Tre

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
globenewswire.com
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises t
benzinga.com
HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR)
benzinga.com
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN184

Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline fr

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
globenewswire.com
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Globa

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
zacks.com
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
globenewswire.com
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Impr

WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Pati

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
globenewswire.com
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper

WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
globenewswire.com
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Dise

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Comp
benzinga.com
Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the a

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
globenewswire.com
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Compan

Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
defenseworld.net
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
globenewswire.com
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopa
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Ta

Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with
benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
zacks.com
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins l

Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down After Earnings Miss
defenseworld.net
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down After Earnings Miss

Shares of Monopar Therapeutics Inc. (NASDAQ: MNPR - Get Free Report) gapped down prior to trading on

This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
benzinga.com
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
benzinga.com
Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123

Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy
benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ma
benzinga.com
Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the a

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
globenewswire.com
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ra
benzinga.com
Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price

Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR)

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
globenewswire.com
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Analysts
defenseworld.net
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Analysts

Monopar Therapeutics Inc. (NASDAQ: MNPR - Get Free Report) has been given an average rating of "Buy"

Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
zacks.com
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 42.5% in Mo

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
globenewswire.com
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For

benzinga.com
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target o

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Ove
benzinga.com
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142

Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Bu
benzinga.com
Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115

Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperf
benzinga.com
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR)
benzinga.com
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
benzinga.com
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises

benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and r

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock an

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopa

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
globenewswire.com
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALX

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Comp
benzinga.com
Lake Street Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $1

Lake Street initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announc
benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $60 Price Target

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ma
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $87 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
Monopar To Present 6-Year Data Showing Sustained Neurological Improvement With ALXN1840 in Wilson Di

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that new data on the long-term neurological effica